$NBIO a clinical-stage biotechnology Company focu
Post# of 144521
(Total Views: 139)
Posted On: 10/04/2022 8:34:48 AM
$NBIO a clinical-stage biotechnology Company focused on the development of monoclonal antibodies targeting various cancer types, announced today that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab ("PTB"
as a treatment for Primary and Metastatic Brain Cancers.
Sean Carrick, Nascent CEO, explains, "We are enthusiastically encouraging anyone interested in screening for the trial to do so in a timely manner. This cohort of patients will likely be the final one in this trial, and new patient enrollment will cease until our Phase II research gets underway."
Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term ‘Pritumumab'.
Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research.
PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.
as a treatment for Primary and Metastatic Brain Cancers. Sean Carrick, Nascent CEO, explains, "We are enthusiastically encouraging anyone interested in screening for the trial to do so in a timely manner. This cohort of patients will likely be the final one in this trial, and new patient enrollment will cease until our Phase II research gets underway."
Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term ‘Pritumumab'.
Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research.
PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.
(0)
(0)Scroll down for more posts ▼